Chief Executive Officer
Revilico Inc
Christopher Korban is the Co-Founder and CEO of Revilico Inc., an AI-driven company pioneering an end to end operating system for small molecule drug discovery. At Revilico, he leads a multidisciplinary team of engineers, scientists, and AI specialists in building a platform that integrates generative chemistry, machine learning, and disease modeling to reduce time and cost in pharmaceutical R&D. With strategic guidance from advisors affiliated with Pfizer, Genentech, Stanford, Amgen, and Harvard, Christopher is positioning Revilico to transform how small molecule therapies are discovered and optimized.
A Biomedical Engineer by training, Christopher studied at UCLA, where he conducted research across multiple labs. At the Di Carlo Lab, he investigated point-of-care technologies and diagnostic devices. In the I2BL Lab, he developed biomarker and metabolite biosensors for implantable and wearable applications. As part of the Wright Lab, he focused on polymersome drug delivery systems for cancer and diabetes, advancing protein–polymer bioconjugation strategies. At the UCLA Molecular Screening Shared Resource with Dr. Robert Damoiseaux, he contributed to high-throughput screening campaigns to identify novel therapeutic candidates.
Christopher’s passion lies at the intersection of engineering, business, and biotechnology, with a mission to bridge AI with the wet lab and deliver next-generation therapies for patients worldwide.
Disclosure information not submitted.
Virtual Cells in Drug Discovery: A Physics-to-Intelligence Journey
Monday, November 10, 2025
3:00 PM - 3:15 PM CT